Skip to content

Efficacy and safety of radioiodine combined with Lugol's Solution for remnant ablation in patients with differentiated thyroid cancer: a randomized controlled clinical trial

Efficacy and safety of radioiodine combined with Lugol's Solution for remnant ablation in patients with differentiated thyroid cancer: a randomized controlled clinical trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900027705
Enrollment
Unknown
Registered
2019-11-24
Start date
2020-05-01
Completion date
Unknown
Last updated
2020-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

differentiated thyroid carcinoma

Interventions

A:radioiodine and LS
B:radioiodine only

Sponsors

Shanghai Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. pathological confirmation of DTC; 2. 1-6 months after total or near total thyroidectomy; 3. patients are refered to our department for radioiodine ablation treatment; 4. thyroid hormone withdraw for at least 3 weeks and TSH 30UI/mL; 5. stimulated thyroglobulin =10ng/ml; 6. thyroglobulin antibody <=115 UI/mL; 7. total removal of known tumors (R0); 8. Low iodine diet for 2 weeks before treatment; 9. aged 18-70 years.

Exclusion criteria

Exclusion criteria: 1. high risk pathological types of PTC: high columnar, low differentiation, etc., 2. gross extrathyroidal extension during the surgery; 3. local recurrence, metastasis or distant metastasis has been confirmed or suspected before treatment; 4. iodine enhanced CT scan was performed in 3 months before treatment; 5. in addition to thyoidectomy and thyroid hormone replacement therapy, the patient has been received other treatments, such as radiotherapy, etc., 6. patient with second or more primary malignant tumors; 7. patient with serious diseases, such as angina pectoris, recent heart attack or stroke, severe unstable hypertension, dementia, dialysis, tracheotomy requiring care, learning difficulties, etc., and any patients who may not be able to comply with radiation protection principles or need regular care/medical supervision); 8. pregnant or lactating female; 9. active tuberculosis; 10. history of allergy. 11. radioiodine scan after thyroidectomy

Design outcomes

Primary

MeasureTime frame
treatment efficacy;

Secondary

MeasureTime frame
treatment safety;

Countries

China

Contacts

Public ContactChentian Shen

Shanghai Jiao Tong University

shenchentian@126.com+86 15216616515

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 26, 2026